• Something wrong with this record ?

Personal comorbidities and their subsequent risks for liver, gallbladder and bile duct cancers

K. Hemminki, K. Sundquist, J. Sundquist, A. Försti, V. Liska, A. Hemminki, X. Li

. 2023 ; 152 (6) : 1107-1114. [pub] 20221010

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc23003817

Many environmental risk factors for hepatobiliary cancers are known but whether they are associated with specific cancer types is unclear. We present here a novel approach of assessing standardized incidence ratios (SIRs) of previously diagnosed comorbidities for hepatocellular carcinoma (HCC), gallbladder cancer (GBC), cholangiocarcinoma (CCA) and ampullary cancer. The 13 comorbidities included alcohol and nonalcohol related liver disease, chronic obstructive pulmonary disease, gallstone disease, viral and other kinds of hepatitis, infection of bile ducts, hepatic and other autoimmune diseases, obesity and diabetes. Patients were identified from the Swedish Inpatient Register from 1987 to 2018, and their cancers were followed from 1997 onwards. SIRs for HCC were 80 to 100 in men and women diagnosed with hepatitis C virus and they were also >10 in patients diagnosed with hepatitis B virus, other kind of hepatitis, hepatic autoimmune disease and nonalcohol related liver disease. Many of these risks, as well as alcohol related liver disease, were either specific to HCC or were shared with intrahepatic CCA. For GBC, CCA and ampullary cancer infection of bile ducts was the main risk factor. Gallstone disease, nonhepatic autoimmune diseases and diabetes were associated with all hepatobiliary cancers. The limitations of the study include inability to cover some rare risk factors and limited follow-up time. Many of the considered comorbidities are characterized by chronic inflammation and/or overt immune disturbance in autoimmune diseases. The results suggest that local chronic inflammation and a related immune disturbance is the carcinogenic trigger for all these cancers.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23003817
003      
CZ-PrNML
005      
20230425140912.0
007      
ta
008      
230418s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/ijc.34308 $2 doi
035    __
$a (PubMed)36196489
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Hemminki, Kari $u Faculty of Medicine and Biomedical Center in Pilsen, Biomedical Center, Charles University in Prague, Pilsen $u Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany $u Center for Primary Health Care Research, Lund University, Malmö $1 https://orcid.org/0000000227693316 $7 mzk20201092711
245    10
$a Personal comorbidities and their subsequent risks for liver, gallbladder and bile duct cancers / $c K. Hemminki, K. Sundquist, J. Sundquist, A. Försti, V. Liska, A. Hemminki, X. Li
520    9_
$a Many environmental risk factors for hepatobiliary cancers are known but whether they are associated with specific cancer types is unclear. We present here a novel approach of assessing standardized incidence ratios (SIRs) of previously diagnosed comorbidities for hepatocellular carcinoma (HCC), gallbladder cancer (GBC), cholangiocarcinoma (CCA) and ampullary cancer. The 13 comorbidities included alcohol and nonalcohol related liver disease, chronic obstructive pulmonary disease, gallstone disease, viral and other kinds of hepatitis, infection of bile ducts, hepatic and other autoimmune diseases, obesity and diabetes. Patients were identified from the Swedish Inpatient Register from 1987 to 2018, and their cancers were followed from 1997 onwards. SIRs for HCC were 80 to 100 in men and women diagnosed with hepatitis C virus and they were also >10 in patients diagnosed with hepatitis B virus, other kind of hepatitis, hepatic autoimmune disease and nonalcohol related liver disease. Many of these risks, as well as alcohol related liver disease, were either specific to HCC or were shared with intrahepatic CCA. For GBC, CCA and ampullary cancer infection of bile ducts was the main risk factor. Gallstone disease, nonhepatic autoimmune diseases and diabetes were associated with all hepatobiliary cancers. The limitations of the study include inability to cover some rare risk factors and limited follow-up time. Many of the considered comorbidities are characterized by chronic inflammation and/or overt immune disturbance in autoimmune diseases. The results suggest that local chronic inflammation and a related immune disturbance is the carcinogenic trigger for all these cancers.
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    12
$a hepatocelulární karcinom $x patologie $7 D006528
650    12
$a nádory jater $x epidemiologie $x etiologie $x patologie $7 D008113
650    12
$a ampulla Vateri $x patologie $7 D014670
650    12
$a nádory ductus choledochus $x komplikace $x patologie $7 D003138
650    12
$a cholangiokarcinom $x epidemiologie $x etiologie $x diagnóza $7 D018281
650    12
$a nádory žlučových cest $x epidemiologie $x etiologie $x patologie $7 D001650
650    12
$a nádory žlučníku $x etiologie $x komplikace $7 D005706
650    _2
$a žlučové cesty intrahepatální $x patologie $7 D001653
650    12
$a cholelitiáza $x komplikace $x patologie $7 D002769
650    _2
$a zánět $x patologie $7 D007249
650    12
$a autoimunitní nemoci $7 D001327
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Sundquist, Kristina $u Center for Primary Health Care Research, Lund University, Malmö $u Department of Family Medicine and Community Health, Icahn School of Medicine at Mount Sinai, Mount Sinai, New York, USA $u Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, Mount Sinai, New York, USA $u Department of Functional Pathology, Center for Community-Based Healthcare Research and Education (CoHRE), School of Medicine, Shimane University, Shimane, Japan
700    1_
$a Sundquist, Jan $u Center for Primary Health Care Research, Lund University, Malmö $u Department of Family Medicine and Community Health, Icahn School of Medicine at Mount Sinai, Mount Sinai, New York, USA $u Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, Mount Sinai, New York, USA $u Department of Functional Pathology, Center for Community-Based Healthcare Research and Education (CoHRE), School of Medicine, Shimane University, Shimane, Japan
700    1_
$a Försti, Asta $u Center for Primary Health Care Research, Lund University, Malmö $u Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany $u Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany
700    1_
$a Liska, Vaclav $u Faculty of Medicine and Biomedical Center in Pilsen, Biomedical Center, Charles University in Prague, Pilsen $u Department of Surgery, University Hospital, School of Medicine in Pilsen, Pilsen, Czech Republic
700    1_
$a Hemminki, Akseli $u Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland $u Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland $1 https://orcid.org/0000000171038530
700    1_
$a Li, Xinjun $u Center for Primary Health Care Research, Lund University, Malmö
773    0_
$w MED00002298 $t International journal of cancer $x 1097-0215 $g Roč. 152, č. 6 (2023), s. 1107-1114
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36196489 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425140908 $b ABA008
999    __
$a ok $b bmc $g 1924470 $s 1190026
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 152 $c 6 $d 1107-1114 $e 20221010 $i 1097-0215 $m International journal of cancer $n Int J Cancer $x MED00002298
LZP    __
$a Pubmed-20230418

Find record

Citation metrics

Archiving options